His primary areas of study are Immunology, Immune system, CpG Oligodeoxynucleotide, CpG site and Immunotherapy. The various areas that George J. Weiner examines in his Immunology study include Progressive disease and Cancer, Internal medicine. His Cancer research research extends to the thematically linked field of Immune system.
His biological study spans a wide range of topics, including Cytokine secretion, Oligonucleotide and Lytic cycle. His studies in Immunotherapy integrate themes in fields like Antibody, Rituximab, Cytokine and Clinical trial. The concepts of his Cancer immunotherapy study are interwoven with issues in Interleukin 12, Janus kinase 3 and Adoptive cell transfer.
His scientific interests lie mostly in Immunology, Internal medicine, Cancer research, Antibody and Immunotherapy. The Immune system, Antigen and Complement system research George J. Weiner does as part of his general Immunology study is frequently linked to other disciplines of science, such as CpG Oligodeoxynucleotide, therefore creating a link between diverse domains of science. His CpG Oligodeoxynucleotide research is multidisciplinary, incorporating perspectives in TLR9 and CpG site.
George J. Weiner has included themes like Gastroenterology and Oncology in his Internal medicine study. His Antibody research incorporates themes from Molecular biology and Cytotoxicity. His studies deal with areas such as T cell and Immune tolerance as well as Immunotherapy.
His primary scientific interests are in Internal medicine, Cancer research, Immunology, Immunotherapy and Immune system. George J. Weiner combines subjects such as Gastroenterology and Oncology with his study of Internal medicine. His Cancer research research is multidisciplinary, relying on both Genetic screen, Blockade, Mantle cell lymphoma and In vivo.
The concepts of his Immunology study are interwoven with issues in Cancer and Graft-versus-host disease. His work on Chimeric antigen receptor as part of general Immunotherapy research is frequently linked to CpG site, bridging the gap between disciplines. George J. Weiner brings together Immune system and CpG Oligodeoxynucleotide to produce work in his papers.
George J. Weiner mainly investigates Immunology, Immunotherapy, Immune system, Internal medicine and Lymphoma. His research in Immunology is mostly focused on Cancer immunotherapy. His studies deal with areas such as Cancer research, Hypoxia and Respiratory virus as well as Immunotherapy.
Immune tolerance and T cell are the core of his Immune system study. George J. Weiner focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Oncology and, in certain cases, Virus and Interleukin 6. His research integrates issues of Genetics, Genome-wide association study and Cohort study in his study of Lymphoma.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells.
G. Hartmann;G. J. Weiner;A. M. Krieg.
Proceedings of the National Academy of Sciences of the United States of America (1999)
Rituximab: mechanism of action.
George J. Weiner.
Seminars in Hematology (2010)
Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
George J. Weiner;Hsin-Ming Liu;James E. Wooldridge;Christopher E. Dahle.
Proceedings of the National Academy of Sciences of the United States of America (1997)
Building better monoclonal antibody-based therapeutics.
George J. Weiner.
Nature Reviews Cancer (2015)
Cancer immunotherapy comes of age.
Suzanne L. Topalian;George J. Weiner;Drew M. Pardoll.
Journal of Clinical Oncology (2011)
Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
Krieg Arthur M;Weiner George.
Cancer and inflammation: Promise for biologic therapy
Sandra Demaria;Eli Pikarsky;Michael Karin;Lisa M. Coussens.
Journal of Immunotherapy (2010)
Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL.
K D Heckman;G J Weiner;C S Davis;R G Strauss.
Journal of Clinical Oncology (1997)
Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs
Zuhair K. Ballas;Arthur M. Krieg;Arthur M. Krieg;Arthur M. Krieg;Thomas Warren;Wendy Rasmussen;Wendy Rasmussen.
Journal of Immunology (2001)
Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Amani Makkouk;George J. Weiner.
Cancer Research (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: